Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

About the Report

About the Report

Asia Pacific oral antibiotics market will grow by 4.6% annually with a total addressable market cap of USD 103.3 billion over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.

Highlighted with 35 tables and 62 figures, this 126-page report Asia Pacific Oral Antibiotics Market 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cephalosporin

Cefuroxime Axetil

Cephalexin

Cefixime

Cefpodoxime

Other Cephalosporin

Penicillin

Macrolides

Tetracycline

Quinolones

Sulfonamides

Aminoglycosides

Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Cell Wall Synthesis Inhibitors

Mycolic Acid Inhibitors

RNA Synthesis Inhibitors

DNA Synthesis Inhibitors

Protein Synthesis Inhibitors

Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Natural Antibiotics

Semi-synthetic Antibiotics

Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Broad-spectrum Antibiotics

Narrow-spectrum Antibiotics

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Urinary Tract Infections (UTIS)

Upper Respiratory Tract Infections (URTI)

Lower Respiratory Tract Infections (LRTIs)

Dental Infections

Monotherapies

Combined Therapies

Respiratory Tract Infections (RTIS)

Other Applications

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Brand Antibiotics

Generic Antibiotics

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific oral antibiotics market are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Products


Companies

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories

Astellas Pharma

AstraZeneca Plc

Bayer AG

Bristol Myers Squibb Company

Cipla Inc.

Dr. Reddy's Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline plc.

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)

Mayne Pharma Group Ltd.

MELINTA THERAPEUTICS, INC.

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Table of Contents

Table of Contents

1 Introduction 7

1.1 Industry Definition and Research Scope 7

1.1.1 Industry Definition 7

1.1.2 Research Scope 8

1.2 Research Methodology 11

1.2.1 Overview of Market Research Methodology 11

1.2.2 Market Assumption 12

1.2.3 Secondary Data 12

1.2.4 Primary Data 12

1.2.5 Data Filtration and Model Design 14

1.2.6 Market Size/Share Estimation 15

1.2.7 Research Limitations 16

1.3 Executive Summary 17

2 Market Overview and Dynamics 20

2.1 Market Size and Forecast 20

2.1.1 Impact of COVID-19 on the Market 21

2.2 Major Growth Drivers 23

2.3 Market Restraints and Challenges 27

2.4 Emerging Opportunities and Market Trends 30

2.5 Porter's Fiver Forces Analysis 34

3 Segmentation of Asia Pacific Market by Drug Class 38

3.1 Market Overview by Drug Class 38

3.2 Cephalosporin 40

3.3 Penicillin 42

3.4 Macrolides 43

3.5 Tetracycline 44

3.6 Quinolones 45

3.7 Sulfonamides 46

3.8 Aminoglycosides 47

3.9 Other Drug Classes 48

4 Segmentation of Asia Pacific Market by Action Mechanism 49

4.1 Market Overview by Action Mechanism 49

4.2 Cell Wall Synthesis Inhibitors 51

4.3 Mycolic Acid Inhibitors 52

4.4 RNA Synthesis Inhibitors 53

4.5 DNA Synthesis Inhibitors 54

4.6 Protein Synthesis Inhibitors 55

4.7 Other Mechanisms 56

5 Segmentation of Asia Pacific Market by Drug Origin 57

5.1 Market Overview by Drug Origin 57

5.2 Natural Antibiotics 59

5.3 Semi-synthetic Antibiotics 60

5.4 Synthetic Antibiotics 61

6 Segmentation of Asia Pacific Market by Activity Spectrum 62

6.1 Market Overview by Activity Spectrum 62

6.2 Broad-spectrum Antibiotics 64

6.3 Narrow-spectrum Antibiotics 65

7 Segmentation of Asia Pacific Market by Application 66

7.1 Market Overview by Application 66

7.2 Urinary Tract Infections (UTIS) 68

7.3 Dental Infections 69

7.3.1 Monotherapies for Dental Infections 70

7.3.2 Combined Therapies for Dental Infections 71

7.4 Respiratory Tract Infections (RTIS) 72

7.4.1 Upper Respiratory Tract Infections (URTI) 73

7.4.2 Lower Respiratory Tract Infections (LRTIs) 74

7.5 Other Applications 75

8 Segmentation of Asia Pacific Market by Drug Type 76

8.1 Market Overview by Drug Type 76

8.2 Brand Antibiotics 78

8.3 Generic Antibiotics 79

9 Asia-Pacific Market 2019-2030 by Country 80

9.1 Overview of Asia-Pacific Market 80

9.2 Japan 83

9.3 China 86

9.4 Australia 88

9.5 India 90

9.6 South Korea 92

9.7 Rest of APAC Region 94

10 Competitive Landscape 96

10.1 Overview of Key Vendors 96

10.2 New Product Launch, Partnership, Investment, and M&A 99

10.3 Company Profiles 100

Abbott Laboratories 100

Astellas Pharma 102

AstraZeneca Plc 103

Bayer AG 104

Bristol Myers Squibb Company 105

Cipla Inc. 106

Dr. Reddy's Laboratories Ltd. 107

Eli Lilly and Company 108

F. Hoffmann-La Roche Ltd. 109

Gilead Sciences, Inc. 110

GlaxoSmithKline plc. 111

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 112

Mayne Pharma Group Ltd. 113

MELINTA THERAPEUTICS, INC. 114

Merck KGaA 115

Novartis AG 116

Pfizer Inc. 117

Sanofi 118

Sun Pharmaceutical Industries Ltd. 119

11 Investing in Asia Pacific Market: Risk Assessment and Management 120

11.1 Risk Evaluation of Asia Pacific Market 120

11.2 Critical Success Factors (CSFs) 123

Related Reports and Products 126


List of Figure

Figure 1. Research Method Flow Chart 11

Figure 2. Breakdown of Primary Research 13

Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15

Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17

Figure 5. Asia Pacific Oral Antibiotics Market, 2019-2030, USD mn 20

Figure 6. Impact of COVID-19 on Business 21

Figure 7. Primary Drivers and Impact Factors of Asia Pacific Oral Antibiotics Market 23

Figure 8. GDP per capita in the World, 1960-2018, USD thousand 26

Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26

Figure 10. Primary Restraints and Impact Factors of Asia Pacific Oral Antibiotics Market 27

Figure 11. Investment Opportunity Analysis 31

Figure 12. Porter's Fiver Forces Analysis of Asia Pacific Oral Antibiotics Market 34

Figure 13. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Class, 2019-2030, % of Revenue 39

Figure 14. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Class, Value (USD mn) and Share (%) 39

Figure 15. Asia Pacific Oral Antibiotics Market: Cephalosporin, 2019-2030, USD mn 40

Figure 16. Asia Pacific Oral Antibiotics Market: Penicillin, 2019-2030, USD mn 42

Figure 17. Asia Pacific Oral Antibiotics Market: Macrolides, 2019-2030, USD mn 43

Figure 18. Asia Pacific Oral Antibiotics Market: Tetracycline, 2019-2030, USD mn 44

Figure 19. Asia Pacific Oral Antibiotics Market: Quinolones, 2019-2030, USD mn 45

Figure 20. Asia Pacific Oral Antibiotics Market: Sulfonamides, 2019-2030, USD mn 46

Figure 21. Asia Pacific Oral Antibiotics Market: Aminoglycosides, 2019-2030, USD mn 47

Figure 22. Asia Pacific Oral Antibiotics Market: Other Drug Classes, 2019-2030, USD mn 48

Figure 23. Breakdown of Asia Pacific Oral Antibiotics Market by Action Mechanism, 2019-2030, % of Sales Revenue 50

Figure 24. Asia Pacific Addressable Market Cap in 2020-2030 by Action Mechanism, Value (USD mn) and Share (%) 50

Figure 25. Asia Pacific Oral Antibiotics Market: Cell Wall Synthesis Inhibitors, 2019-2030, USD mn 51

Figure 26. Asia Pacific Oral Antibiotics Market: Mycolic Acid Inhibitors, 2019-2030, USD mn 52

Figure 27. Asia Pacific Oral Antibiotics Market: RNA Synthesis Inhibitors, 2019-2030, USD mn 53

Figure 28. Asia Pacific Oral Antibiotics Market: DNA Synthesis Inhibitors, 2019-2030, USD mn 54

Figure 29. Asia Pacific Oral Antibiotics Market: Protein Synthesis Inhibitors, 2019-2030, USD mn 55

Figure 30. Asia Pacific Oral Antibiotics Market: Other Mechanisms, 2019-2030, USD mn 56

Figure 31. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Origin, 2019-2030, % of Sales Revenue 58

Figure 32. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Origin, Value (USD mn) and Share (%) 58

Figure 33. Asia Pacific Oral Antibiotics Market: Natural Antibiotics, 2019-2030, USD mn 59

Figure 34. Asia Pacific Oral Antibiotics Market: Semi-synthetic Antibiotics, 2019-2030, USD mn 60

Figure 35. Asia Pacific Oral Antibiotics Market: Synthetic Antibiotics, 2019-2030, USD mn 61

Figure 36. Breakdown of Asia Pacific Oral Antibiotics Market by Activity Spectrum, 2019-2030, % of Revenue 63

Figure 37. Asia Pacific Addressable Market Cap in 2020-2030 by Activity Spectrum, Value (USD mn) and Share (%) 63

Figure 38. Asia Pacific Oral Antibiotics Market: Broad-spectrum Antibiotics, 2019-2030, USD mn 64

Figure 39. Asia Pacific Oral Antibiotics Market: Narrow-spectrum Antibiotics, 2019-2030, USD mn 65

Figure 40. Breakdown of Asia Pacific Oral Antibiotics Market by Application, 2019-2030, % of Revenue 67

Figure 41. Asia Pacific Addressable Market Cap in 2020-2030 by Application, Value (USD mn) and Share (%) 67

Figure 42. Asia Pacific Oral Antibiotics Market: Urinary Tract Infections (UTIS), 2019-2030, USD mn 68

Figure 43. Asia Pacific Oral Antibiotics Market: Dental Infections, 2019-2030, USD mn 69

Figure 44. Asia Pacific Oral Antibiotics Market: Monotherapies for Dental Infections, 2019-2030, USD mn 70

Figure 45. Asia Pacific Oral Antibiotics Market: Combined Therapies for Dental Infections, 2019-2030, USD mn 71

Figure 46. Asia Pacific Oral Antibiotics Market: Respiratory Tract Infections (RTIS), 2019-2030, USD mn 72

Figure 47. Asia Pacific Oral Antibiotics Market: Upper Respiratory Tract Infections (URTI), 2019-2030, USD mn 73

Figure 48. Asia Pacific Oral Antibiotics Market: Lower Respiratory Tract Infections (LRTIs), 2019-2030, USD mn 74

Figure 49. Asia Pacific Oral Antibiotics Market: Other Applications, 2019-2030, USD mn 75

Figure 50. Breakdown of Asia Pacific Oral Antibiotics Market by Drug Type, 2019-2030, % of Revenue 76

Figure 51. Asia Pacific Addressable Market Cap in 2020-2030 by Drug Type, Value (USD bn) and Share (%) 77

Figure 52. Asia Pacific Oral Antibiotics Market: Brand Antibiotics, 2019-2030, USD bn 78

Figure 53. Asia Pacific Oral Antibiotics Market: Generic Antibiotics, 2019-2030, USD bn 79

Figure 54. Breakdown of APAC Oral Antibiotics Market by Country, 2019 and 2030, % of Revenue 81

Figure 55. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value (USD bn) and Share (%) 82

Figure 56. Oral Antibiotics Market in Japan, 2019-2030, USD bn 84

Figure 57. Oral Antibiotics Market in China, 2019-2030, USD bn 86

Figure 58. Oral Antibiotics Market in Australia, 2019-2030, USD bn 88

Figure 59. Oral Antibiotics Market in India, 2019-2030, USD bn 90

Figure 60. Oral Antibiotics Market in South Korea, 2019-2030, USD bn 92

Figure 61. Oral Antibiotics Market in Rest of APAC, 2019-2030, USD bn 94

Figure 62. Growth Stage of Asia Pacific Oral Antibiotics Industry over the Forecast Period 96


List of Table

Table 1. Snapshot of Asia Pacific Oral Antibiotics Market, 2019-2030 18

Table 2. Main Product Trends and Market Opportunities in Asia Pacific Oral Antibiotics Market 30

Table 3. Asia Pacific Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 38

Table 4. Asia Pacific Oral Antibiotics Market: Cephalosporin by Molecule, 2019-2030, USD mn 41

Table 5. Asia Pacific Oral Antibiotics Market by Action Mechanism, 2019-2030, USD mn 49

Table 6. Asia Pacific Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 57

Table 7. Asia Pacific Oral Antibiotics Market by Activity Spectrum, 2019-2030, USD mn 62

Table 8. Asia Pacific Oral Antibiotics Market by Application, 2019-2030, USD mn 66

Table 9. Asia Pacific Oral Antibiotics Market: Dental Infections by Type, 2019-2030, USD mn 69

Table 10. Asia Pacific Oral Antibiotics Market: Respiratory Tract Infections (RTIS) by Type, 2019-2030, USD mn 72

Table 11. Asia Pacific Oral Antibiotics Market by Drug Type, 2019-2030, USD bn 76

Table 12. APAC Oral Antibiotics Market by Country, 2019-2030, USD bn 81

Table 13. Japan Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 85

Table 14. Japan Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 85

Table 15. Japan Oral Antibiotics Market by Application, 2019-2030, USD mn 85

Table 16. China Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 87

Table 17. China Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 87

Table 18. China Oral Antibiotics Market by Application, 2019-2030, USD mn 87

Table 19. Australia Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 89

Table 20. Australia Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 89

Table 21. Australia Oral Antibiotics Market by Application, 2019-2030, USD mn 89

Table 22. India Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 91

Table 23. India Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 91

Table 24. India Oral Antibiotics Market by Application, 2019-2030, USD mn 91

Table 25. South Korea Oral Antibiotics Market by Drug Class, 2019-2030, USD mn 93

Table 26. South Korea Oral Antibiotics Market by Drug Origin, 2019-2030, USD mn 93

Table 27. South Korea Oral Antibiotics Market by Application, 2019-2030, USD mn 93

Table 28. Oral Antibiotics Market in Rest of APAC by Country, 2019-2030, USD bn 95

Table 29. Abbott Laboratories: Company Snapshot 100

Table 30. Abbott Laboratories: Business Segmentation 100

Table 31. Abbott Laboratories: Product Portfolio 101

Table 32. Abbott Laboratories: Revenue, 2016-2018, USD mn 101

Table 33. Abbott Laboratories: Recent Developments 101

Table 34. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030 121

Table 35. Critical Success Factors and Key Takeaways 124

You can also purchase parts of this report. Do you want to check out a section wise price list?

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022

What Our Clients Say About Us

Want the same for your business? Talk To Our Expert